nodes	percent_of_prediction	percent_of_DWPC	metapath
Finasteride—Progesterone—uterine cancer	0.372	1	CrCtD
Finasteride—SRD5A2—uterine cancer	0.257	1	CbGaD
Finasteride—Drostanolone—Progesterone—uterine cancer	0.0355	0.154	CrCrCtD
Finasteride—Dydrogesterone—Medroxyprogesterone Acetate—uterine cancer	0.0324	0.14	CrCrCtD
Finasteride—Dydrogesterone—Progesterone—uterine cancer	0.0282	0.122	CrCrCtD
Finasteride—Medrysone—Medroxyprogesterone Acetate—uterine cancer	0.026	0.113	CrCrCtD
Finasteride—Medrysone—Progesterone—uterine cancer	0.0227	0.0984	CrCrCtD
Finasteride—CYP3A7—Progesterone—uterine cancer	0.0203	0.248	CbGbCtD
Finasteride—CYP3A7-CYP3A51P—Progesterone—uterine cancer	0.0203	0.248	CbGbCtD
Finasteride—Testosterone Propionate—Medroxyprogesterone Acetate—uterine cancer	0.0191	0.0827	CrCrCtD
Finasteride—Progesterone—Medroxyprogesterone Acetate—uterine cancer	0.0191	0.0827	CrCrCtD
Finasteride—Testosterone Propionate—Progesterone—uterine cancer	0.0166	0.0721	CrCrCtD
Finasteride—Testosterone—Medroxyprogesterone Acetate—uterine cancer	0.0166	0.0718	CrCrCtD
Finasteride—CYP3A5—Progesterone—uterine cancer	0.0152	0.186	CbGbCtD
Finasteride—Testosterone—Progesterone—uterine cancer	0.0144	0.0626	CrCrCtD
Finasteride—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.00897	0.109	CbGbCtD
Finasteride—CYP3A5—Etoposide—uterine cancer	0.00682	0.0831	CbGbCtD
Finasteride—CYP3A4—Progesterone—uterine cancer	0.00594	0.0724	CbGbCtD
Finasteride—SRD5A1—Androgen biosynthesis—SRD5A2—uterine cancer	0.0044	0.132	CbGpPWpGaD
Finasteride—CYP3A4—Etoposide—uterine cancer	0.00266	0.0324	CbGbCtD
Finasteride—SRD5A1—Metabolism of steroid hormones and vitamin D—SRD5A2—uterine cancer	0.00183	0.055	CbGpPWpGaD
Finasteride—CYP3A4—Doxorubicin—uterine cancer	0.00181	0.0221	CbGbCtD
Finasteride—AKR1D1—Synthesis of bile acids and bile salts via 24-hydroxycholesterol—AKR1C1—uterine cancer	0.00172	0.0516	CbGpPWpGaD
Finasteride—Dutasteride—SRD5A2—uterine cancer	0.00165	0.742	CrCbGaD
Finasteride—AKR1D1—Synthesis of bile acids and bile salts via 27-hydroxycholesterol—AKR1C1—uterine cancer	0.00163	0.0488	CbGpPWpGaD
Finasteride—AKR1D1—Synthesis of bile acids and bile salts via 24-hydroxycholesterol—AKR1C3—uterine cancer	0.00132	0.0397	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism of steroid hormones and vitamin D—STAR—uterine cancer	0.00132	0.0397	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism of steroid hormones and vitamin D—AKR1B1—uterine cancer	0.00132	0.0397	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism of steroid hormones and vitamin D—STAR—uterine cancer	0.00132	0.0397	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism of steroid hormones and vitamin D—AKR1B1—uterine cancer	0.00132	0.0397	CbGpPWpGaD
Finasteride—Breast tenderness—Progesterone—uterine cancer	0.00127	0.0555	CcSEcCtD
Finasteride—AKR1D1—Synthesis of bile acids and bile salts via 27-hydroxycholesterol—AKR1C3—uterine cancer	0.00125	0.0376	CbGpPWpGaD
Finasteride—Musculoskeletal disorder—Progesterone—uterine cancer	0.00116	0.0506	CcSEcCtD
Finasteride—Breast tenderness—Medroxyprogesterone Acetate—uterine cancer	0.00115	0.0503	CcSEcCtD
Finasteride—Breast cancer—Progesterone—uterine cancer	0.00113	0.0495	CcSEcCtD
Finasteride—AKR1D1—Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol—AKR1C1—uterine cancer	0.00112	0.0335	CbGpPWpGaD
Finasteride—Breast cancer—Medroxyprogesterone Acetate—uterine cancer	0.00103	0.0449	CcSEcCtD
Finasteride—AKR1D1—Synthesis of bile acids and bile salts—AKR1C1—uterine cancer	0.00102	0.0305	CbGpPWpGaD
Finasteride—AKR1D1—Synthesis of bile acids and bile salts via 7alpha-hydroxycholesterol—AKR1C3—uterine cancer	0.000859	0.0258	CbGpPWpGaD
Finasteride—AKR1D1—Bile acid and bile salt metabolism—AKR1C1—uterine cancer	0.000807	0.0242	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism of steroid hormones and vitamin D—CYP11A1—uterine cancer	0.000791	0.0238	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism of steroid hormones and vitamin D—CYP11A1—uterine cancer	0.000791	0.0238	CbGpPWpGaD
Finasteride—AKR1D1—Synthesis of bile acids and bile salts—AKR1C3—uterine cancer	0.000782	0.0235	CbGpPWpGaD
Finasteride—Breast enlargement—Progesterone—uterine cancer	0.000638	0.0279	CcSEcCtD
Finasteride—AKR1D1—Bile acid and bile salt metabolism—AKR1C3—uterine cancer	0.000621	0.0187	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism of steroid hormones and vitamin D—CYP19A1—uterine cancer	0.000582	0.0175	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism of steroid hormones and vitamin D—CYP19A1—uterine cancer	0.000582	0.0175	CbGpPWpGaD
Finasteride—Neoplasm malignant—Progesterone—uterine cancer	0.000485	0.0212	CcSEcCtD
Finasteride—Tenderness—Progesterone—uterine cancer	0.000474	0.0207	CcSEcCtD
Finasteride—Neoplasm malignant—Medroxyprogesterone Acetate—uterine cancer	0.000439	0.0192	CcSEcCtD
Finasteride—Tenderness—Medroxyprogesterone Acetate—uterine cancer	0.00043	0.0188	CcSEcCtD
Finasteride—Neoplasm—Progesterone—uterine cancer	0.000374	0.0163	CcSEcCtD
Finasteride—Swelling—Progesterone—uterine cancer	0.00034	0.0149	CcSEcCtD
Finasteride—Neoplasm—Medroxyprogesterone Acetate—uterine cancer	0.000339	0.0148	CcSEcCtD
Finasteride—AKR1D1—Metapathway biotransformation—AKR1B10—uterine cancer	0.000334	0.01	CbGpPWpGaD
Finasteride—Injury—Progesterone—uterine cancer	0.000327	0.0143	CcSEcCtD
Finasteride—Libido decreased—Progesterone—uterine cancer	0.000324	0.0141	CcSEcCtD
Finasteride—AKR1D1—Metapathway biotransformation—AKR1B1—uterine cancer	0.00031	0.00932	CbGpPWpGaD
Finasteride—Swelling—Medroxyprogesterone Acetate—uterine cancer	0.000309	0.0135	CcSEcCtD
Finasteride—Disturbance in sexual arousal—Progesterone—uterine cancer	0.000298	0.013	CcSEcCtD
Finasteride—Libido decreased—Medroxyprogesterone Acetate—uterine cancer	0.000294	0.0128	CcSEcCtD
Finasteride—Infection—Carboplatin—uterine cancer	0.000279	0.0122	CcSEcCtD
Finasteride—Prostatic disorder—Epirubicin—uterine cancer	0.000279	0.0122	CcSEcCtD
Finasteride—Breast disorder—Progesterone—uterine cancer	0.000271	0.0119	CcSEcCtD
Finasteride—Disturbance in sexual arousal—Medroxyprogesterone Acetate—uterine cancer	0.00027	0.0118	CcSEcCtD
Finasteride—Dydrogesterone—PGR—uterine cancer	0.000261	0.117	CrCbGaD
Finasteride—Prostatic disorder—Doxorubicin—uterine cancer	0.000258	0.0113	CcSEcCtD
Finasteride—Bronchitis—Progesterone—uterine cancer	0.00025	0.0109	CcSEcCtD
Finasteride—Orthostatic hypotension—Medroxyprogesterone Acetate—uterine cancer	0.000249	0.0109	CcSEcCtD
Finasteride—Breast disorder—Medroxyprogesterone Acetate—uterine cancer	0.000246	0.0107	CcSEcCtD
Finasteride—Pain—Carboplatin—uterine cancer	0.00024	0.0105	CcSEcCtD
Finasteride—Influenza—Medroxyprogesterone Acetate—uterine cancer	0.000235	0.0103	CcSEcCtD
Finasteride—AKR1D1—Metapathway biotransformation—AKR1C1—uterine cancer	0.000228	0.00684	CbGpPWpGaD
Finasteride—Bronchitis—Medroxyprogesterone Acetate—uterine cancer	0.000226	0.00988	CcSEcCtD
Finasteride—Sinusitis—Progesterone—uterine cancer	0.000217	0.00949	CcSEcCtD
Finasteride—Rhinitis—Progesterone—uterine cancer	0.000208	0.0091	CcSEcCtD
Finasteride—Pharyngitis—Progesterone—uterine cancer	0.000206	0.00901	CcSEcCtD
Finasteride—Oedema peripheral—Progesterone—uterine cancer	0.000205	0.00894	CcSEcCtD
Finasteride—AKR1D1—Metapathway biotransformation—GPX3—uterine cancer	0.0002	0.00601	CbGpPWpGaD
Finasteride—Sinusitis—Medroxyprogesterone Acetate—uterine cancer	0.000197	0.0086	CcSEcCtD
Finasteride—Immune system disorder—Progesterone—uterine cancer	0.000188	0.0082	CcSEcCtD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.000187	0.00563	CbGpPWpGaD
Finasteride—Pharyngitis—Medroxyprogesterone Acetate—uterine cancer	0.000187	0.00816	CcSEcCtD
Finasteride—AKR1D1—Metapathway biotransformation—CYP11A1—uterine cancer	0.000186	0.00558	CbGpPWpGaD
Finasteride—Oedema peripheral—Medroxyprogesterone Acetate—uterine cancer	0.000186	0.0081	CcSEcCtD
Finasteride—Mental disorder—Progesterone—uterine cancer	0.000182	0.00795	CcSEcCtD
Finasteride—AKR1D1—Metapathway biotransformation—AKR1C3—uterine cancer	0.000175	0.00527	CbGpPWpGaD
Finasteride—Swelling—Etoposide—uterine cancer	0.000174	0.00761	CcSEcCtD
Finasteride—CYP3A4—Benzo(a)pyrene metabolism—AKR1C1—uterine cancer	0.000174	0.00523	CbGpPWpGaD
Finasteride—Immune system disorder—Medroxyprogesterone Acetate—uterine cancer	0.00017	0.00743	CcSEcCtD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	0.000167	0.00502	CbGpPWpGaD
Finasteride—Angioedema—Progesterone—uterine cancer	0.000165	0.00722	CcSEcCtD
Finasteride—Mental disorder—Medroxyprogesterone Acetate—uterine cancer	0.000165	0.00721	CcSEcCtD
Finasteride—Angioedema—Medroxyprogesterone Acetate—uterine cancer	0.00015	0.00654	CcSEcCtD
Finasteride—Infection—Progesterone—uterine cancer	0.000147	0.00641	CcSEcCtD
Finasteride—Pharyngitis—Dactinomycin—uterine cancer	0.000146	0.00637	CcSEcCtD
Finasteride—Neoplasm malignant—Epirubicin—uterine cancer	0.000139	0.00607	CcSEcCtD
Finasteride—Hypotension—Progesterone—uterine cancer	0.000138	0.00603	CcSEcCtD
Finasteride—AKR1D1—Metapathway biotransformation—CYP19A1—uterine cancer	0.000137	0.0041	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.000135	0.00407	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.000135	0.00407	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.000135	0.00407	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.000135	0.00407	CbGpPWpGaD
Finasteride—CYP3A4—Benzo(a)pyrene metabolism—AKR1C3—uterine cancer	0.000134	0.00402	CbGpPWpGaD
Finasteride—Infection—Medroxyprogesterone Acetate—uterine cancer	0.000133	0.00581	CcSEcCtD
Finasteride—Dyspnoea—Progesterone—uterine cancer	0.000132	0.00575	CcSEcCtD
Finasteride—Somnolence—Progesterone—uterine cancer	0.000131	0.00573	CcSEcCtD
Finasteride—Drostanolone—CYP19A1—uterine cancer	0.000129	0.058	CrCbGaD
Finasteride—Neoplasm malignant—Doxorubicin—uterine cancer	0.000129	0.00562	CcSEcCtD
Finasteride—Pain—Progesterone—uterine cancer	0.000126	0.00551	CcSEcCtD
Finasteride—Hypotension—Medroxyprogesterone Acetate—uterine cancer	0.000125	0.00546	CcSEcCtD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—STAR—uterine cancer	0.000121	0.00363	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	0.000121	0.00363	CbGpPWpGaD
Finasteride—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.000119	0.00521	CcSEcCtD
Finasteride—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.000119	0.0052	CcSEcCtD
Finasteride—Urticaria—Progesterone—uterine cancer	0.000117	0.00512	CcSEcCtD
Finasteride—Hypersensitivity—Progesterone—uterine cancer	0.000109	0.00475	CcSEcCtD
Finasteride—Neoplasm—Epirubicin—uterine cancer	0.000107	0.00469	CcSEcCtD
Finasteride—Urticaria—Medroxyprogesterone Acetate—uterine cancer	0.000106	0.00464	CcSEcCtD
Finasteride—Asthenia—Progesterone—uterine cancer	0.000106	0.00463	CcSEcCtD
Finasteride—Pruritus—Progesterone—uterine cancer	0.000104	0.00456	CcSEcCtD
Finasteride—Infection—Dactinomycin—uterine cancer	0.000104	0.00453	CcSEcCtD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	9.95e-05	0.00299	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	9.95e-05	0.00299	CbGpPWpGaD
Finasteride—Neoplasm—Doxorubicin—uterine cancer	9.93e-05	0.00434	CcSEcCtD
Finasteride—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	9.86e-05	0.00431	CcSEcCtD
Finasteride—Dizziness—Progesterone—uterine cancer	9.76e-05	0.00426	CcSEcCtD
Finasteride—Immune system disorder—Etoposide—uterine cancer	9.6e-05	0.00419	CcSEcCtD
Finasteride—Asthenia—Medroxyprogesterone Acetate—uterine cancer	9.6e-05	0.00419	CcSEcCtD
Finasteride—Pruritus—Medroxyprogesterone Acetate—uterine cancer	9.47e-05	0.00413	CcSEcCtD
Finasteride—Rash—Progesterone—uterine cancer	9.31e-05	0.00407	CcSEcCtD
Finasteride—Dermatitis—Progesterone—uterine cancer	9.3e-05	0.00406	CcSEcCtD
Finasteride—Headache—Progesterone—uterine cancer	9.25e-05	0.00404	CcSEcCtD
Finasteride—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	9.25e-05	0.00278	CbGpPWpGaD
Finasteride—CYP3A7—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	9.12e-05	0.00274	CbGpPWpGaD
Finasteride—Pain—Dactinomycin—uterine cancer	8.92e-05	0.0039	CcSEcCtD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	8.86e-05	0.00266	CbGpPWpGaD
Finasteride—Dizziness—Medroxyprogesterone Acetate—uterine cancer	8.85e-05	0.00386	CcSEcCtD
Finasteride—Rash—Medroxyprogesterone Acetate—uterine cancer	8.44e-05	0.00368	CcSEcCtD
Finasteride—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	8.43e-05	0.00368	CcSEcCtD
Finasteride—Headache—Medroxyprogesterone Acetate—uterine cancer	8.38e-05	0.00366	CcSEcCtD
Finasteride—SRD5A1—Metabolism—NDUFB11—uterine cancer	8.35e-05	0.00251	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—NDUFB11—uterine cancer	8.35e-05	0.00251	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—SRD5A2—uterine cancer	8.35e-05	0.00251	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	8.11e-05	0.00244	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	8.11e-05	0.00244	CbGpPWpGaD
Finasteride—Orthostatic hypotension—Epirubicin—uterine cancer	7.87e-05	0.00344	CcSEcCtD
Finasteride—Breast disorder—Epirubicin—uterine cancer	7.78e-05	0.0034	CcSEcCtD
Finasteride—Hypersensitivity—Dactinomycin—uterine cancer	7.69e-05	0.00336	CcSEcCtD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	7.66e-05	0.0023	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	7.66e-05	0.0023	CbGpPWpGaD
Finasteride—Infection—Etoposide—uterine cancer	7.5e-05	0.00328	CcSEcCtD
Finasteride—CYP3A7—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	7.5e-05	0.00225	CbGpPWpGaD
Finasteride—Asthenia—Dactinomycin—uterine cancer	7.49e-05	0.00327	CcSEcCtD
Finasteride—Influenza—Epirubicin—uterine cancer	7.44e-05	0.00325	CcSEcCtD
Finasteride—AKR1D1—Metabolism—NDUFB11—uterine cancer	7.44e-05	0.00224	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—SRD5A2—uterine cancer	7.44e-05	0.00224	CbGpPWpGaD
Finasteride—Orthostatic hypotension—Doxorubicin—uterine cancer	7.28e-05	0.00318	CcSEcCtD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	7.23e-05	0.00217	CbGpPWpGaD
Finasteride—Breast disorder—Doxorubicin—uterine cancer	7.2e-05	0.00315	CcSEcCtD
Finasteride—Bronchitis—Epirubicin—uterine cancer	7.16e-05	0.00313	CcSEcCtD
Finasteride—CYP3A7—Metapathway biotransformation—AKR1B10—uterine cancer	7.06e-05	0.00212	CbGpPWpGaD
Finasteride—Hypotension—Etoposide—uterine cancer	7.06e-05	0.00308	CcSEcCtD
Finasteride—Influenza—Doxorubicin—uterine cancer	6.89e-05	0.00301	CcSEcCtD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	6.82e-05	0.00205	CbGpPWpGaD
Finasteride—CYP3A7—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	6.8e-05	0.00204	CbGpPWpGaD
Finasteride—Dyspnoea—Etoposide—uterine cancer	6.73e-05	0.00294	CcSEcCtD
Finasteride—Somnolence—Etoposide—uterine cancer	6.71e-05	0.00293	CcSEcCtD
Finasteride—CYP3A7—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	6.71e-05	0.00202	CbGpPWpGaD
Finasteride—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	6.68e-05	0.00201	CbGpPWpGaD
Finasteride—Bronchitis—Doxorubicin—uterine cancer	6.62e-05	0.00289	CcSEcCtD
Finasteride—Testosterone—CYP11A1—uterine cancer	6.61e-05	0.0297	CrCbGaD
Finasteride—CYP3A5—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	6.6e-05	0.00198	CbGpPWpGaD
Finasteride—Rash—Dactinomycin—uterine cancer	6.58e-05	0.00287	CcSEcCtD
Finasteride—CYP3A7—Metapathway biotransformation—AKR1B1—uterine cancer	6.56e-05	0.00197	CbGpPWpGaD
Finasteride—Pain—Etoposide—uterine cancer	6.46e-05	0.00282	CcSEcCtD
Finasteride—Sinusitis—Epirubicin—uterine cancer	6.23e-05	0.00272	CcSEcCtD
Finasteride—SRD5A2—Metabolism—AKR1B1—uterine cancer	6.03e-05	0.00181	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—STAR—uterine cancer	6.03e-05	0.00181	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—STAR—uterine cancer	6.03e-05	0.00181	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—AKR1B1—uterine cancer	6.03e-05	0.00181	CbGpPWpGaD
Finasteride—Urticaria—Etoposide—uterine cancer	6e-05	0.00262	CcSEcCtD
Finasteride—Rhinitis—Epirubicin—uterine cancer	5.97e-05	0.00261	CcSEcCtD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	5.96e-05	0.00179	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	5.96e-05	0.00179	CbGpPWpGaD
Finasteride—Pharyngitis—Epirubicin—uterine cancer	5.91e-05	0.00258	CcSEcCtD
Finasteride—Oedema peripheral—Epirubicin—uterine cancer	5.87e-05	0.00256	CcSEcCtD
Finasteride—Sinusitis—Doxorubicin—uterine cancer	5.76e-05	0.00252	CcSEcCtD
Finasteride—Hypersensitivity—Etoposide—uterine cancer	5.56e-05	0.00243	CcSEcCtD
Finasteride—Rhinitis—Doxorubicin—uterine cancer	5.53e-05	0.00241	CcSEcCtD
Finasteride—CYP3A7—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	5.51e-05	0.00166	CbGpPWpGaD
Finasteride—Pharyngitis—Doxorubicin—uterine cancer	5.47e-05	0.00239	CcSEcCtD
Finasteride—Oedema peripheral—Doxorubicin—uterine cancer	5.43e-05	0.00237	CcSEcCtD
Finasteride—Asthenia—Etoposide—uterine cancer	5.42e-05	0.00237	CcSEcCtD
Finasteride—CYP3A5—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	5.42e-05	0.00163	CbGpPWpGaD
Finasteride—Immune system disorder—Epirubicin—uterine cancer	5.38e-05	0.00235	CcSEcCtD
Finasteride—AKR1D1—Metabolism—STAR—uterine cancer	5.38e-05	0.00162	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—AKR1B1—uterine cancer	5.38e-05	0.00162	CbGpPWpGaD
Finasteride—Pruritus—Etoposide—uterine cancer	5.34e-05	0.00233	CcSEcCtD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	5.32e-05	0.0016	CbGpPWpGaD
Finasteride—Progesterone—PGR—uterine cancer	5.28e-05	0.0237	CrCbGaD
Finasteride—Mental disorder—Epirubicin—uterine cancer	5.22e-05	0.00228	CcSEcCtD
Finasteride—CYP3A5—Metapathway biotransformation—AKR1B10—uterine cancer	5.1e-05	0.00153	CbGpPWpGaD
Finasteride—Dizziness—Etoposide—uterine cancer	4.99e-05	0.00218	CcSEcCtD
Finasteride—Immune system disorder—Doxorubicin—uterine cancer	4.98e-05	0.00218	CcSEcCtD
Finasteride—CYP3A5—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	4.92e-05	0.00148	CbGpPWpGaD
Finasteride—CYP3A5—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	4.85e-05	0.00146	CbGpPWpGaD
Finasteride—Mental disorder—Doxorubicin—uterine cancer	4.83e-05	0.00211	CcSEcCtD
Finasteride—CYP3A7—Metapathway biotransformation—AKR1C1—uterine cancer	4.82e-05	0.00145	CbGpPWpGaD
Finasteride—Rash—Etoposide—uterine cancer	4.76e-05	0.00208	CcSEcCtD
Finasteride—Dermatitis—Etoposide—uterine cancer	4.76e-05	0.00208	CcSEcCtD
Finasteride—CYP3A5—Metapathway biotransformation—AKR1B1—uterine cancer	4.74e-05	0.00143	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—POLD1—uterine cancer	4.74e-05	0.00142	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—POLD1—uterine cancer	4.74e-05	0.00142	CbGpPWpGaD
Finasteride—Headache—Etoposide—uterine cancer	4.73e-05	0.00207	CcSEcCtD
Finasteride—SRD5A2—Metabolism—AKR1C1—uterine cancer	4.43e-05	0.00133	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—AKR1C1—uterine cancer	4.43e-05	0.00133	CbGpPWpGaD
Finasteride—CYP3A7—Metapathway biotransformation—GPX3—uterine cancer	4.23e-05	0.00127	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—POLD1—uterine cancer	4.22e-05	0.00127	CbGpPWpGaD
Finasteride—Infection—Epirubicin—uterine cancer	4.21e-05	0.00184	CcSEcCtD
Finasteride—CYP3A5—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	3.99e-05	0.0012	CbGpPWpGaD
Finasteride—CYP3A7—Biological oxidations—CYP11A1—uterine cancer	3.98e-05	0.0012	CbGpPWpGaD
Finasteride—Hypotension—Epirubicin—uterine cancer	3.96e-05	0.00173	CcSEcCtD
Finasteride—AKR1D1—Metabolism—AKR1C1—uterine cancer	3.95e-05	0.00119	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—RRM2—uterine cancer	3.95e-05	0.00119	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—RRM2—uterine cancer	3.95e-05	0.00119	CbGpPWpGaD
Finasteride—CYP3A7—Metapathway biotransformation—CYP11A1—uterine cancer	3.93e-05	0.00118	CbGpPWpGaD
Finasteride—Infection—Doxorubicin—uterine cancer	3.89e-05	0.0017	CcSEcCtD
Finasteride—SRD5A2—Metabolism—DCN—uterine cancer	3.83e-05	0.00115	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—DCN—uterine cancer	3.83e-05	0.00115	CbGpPWpGaD
Finasteride—Dyspnoea—Epirubicin—uterine cancer	3.77e-05	0.00165	CcSEcCtD
Finasteride—Somnolence—Epirubicin—uterine cancer	3.76e-05	0.00164	CcSEcCtD
Finasteride—CYP3A7—Metapathway biotransformation—AKR1C3—uterine cancer	3.71e-05	0.00111	CbGpPWpGaD
Finasteride—Hypotension—Doxorubicin—uterine cancer	3.66e-05	0.0016	CcSEcCtD
Finasteride—Pain—Epirubicin—uterine cancer	3.62e-05	0.00158	CcSEcCtD
Finasteride—SRD5A1—Metabolism—CYP11A1—uterine cancer	3.61e-05	0.00109	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—CYP11A1—uterine cancer	3.61e-05	0.00109	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—RRM2—uterine cancer	3.52e-05	0.00106	CbGpPWpGaD
Finasteride—Dyspnoea—Doxorubicin—uterine cancer	3.49e-05	0.00153	CcSEcCtD
Finasteride—Somnolence—Doxorubicin—uterine cancer	3.48e-05	0.00152	CcSEcCtD
Finasteride—CYP3A5—Metapathway biotransformation—AKR1C1—uterine cancer	3.48e-05	0.00105	CbGpPWpGaD
Finasteride—Testosterone—CYP19A1—uterine cancer	3.42e-05	0.0153	CrCbGaD
Finasteride—AKR1D1—Metabolism—DCN—uterine cancer	3.42e-05	0.00103	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—AKR1C3—uterine cancer	3.41e-05	0.00102	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—AKR1C3—uterine cancer	3.41e-05	0.00102	CbGpPWpGaD
Finasteride—Urticaria—Epirubicin—uterine cancer	3.36e-05	0.00147	CcSEcCtD
Finasteride—Pain—Doxorubicin—uterine cancer	3.35e-05	0.00146	CcSEcCtD
Finasteride—Progesterone—ESR1—uterine cancer	3.33e-05	0.0149	CrCbGaD
Finasteride—AKR1D1—Metabolism—CYP11A1—uterine cancer	3.22e-05	0.000967	CbGpPWpGaD
Finasteride—Hypersensitivity—Epirubicin—uterine cancer	3.12e-05	0.00136	CcSEcCtD
Finasteride—Urticaria—Doxorubicin—uterine cancer	3.11e-05	0.00136	CcSEcCtD
Finasteride—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	3.11e-05	0.000934	CbGpPWpGaD
Finasteride—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	3.07e-05	0.000922	CbGpPWpGaD
Finasteride—CYP3A5—Metapathway biotransformation—GPX3—uterine cancer	3.06e-05	0.000919	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—AKR1C3—uterine cancer	3.04e-05	0.000913	CbGpPWpGaD
Finasteride—Asthenia—Epirubicin—uterine cancer	3.04e-05	0.00133	CcSEcCtD
Finasteride—Pruritus—Epirubicin—uterine cancer	3e-05	0.00131	CcSEcCtD
Finasteride—CYP3A7—Biological oxidations—CYP19A1—uterine cancer	2.93e-05	0.00088	CbGpPWpGaD
Finasteride—CYP3A7—Metapathway biotransformation—CYP19A1—uterine cancer	2.89e-05	0.000868	CbGpPWpGaD
Finasteride—Hypersensitivity—Doxorubicin—uterine cancer	2.89e-05	0.00126	CcSEcCtD
Finasteride—CYP3A5—Biological oxidations—CYP11A1—uterine cancer	2.88e-05	0.000865	CbGpPWpGaD
Finasteride—CYP3A5—Metapathway biotransformation—CYP11A1—uterine cancer	2.84e-05	0.000853	CbGpPWpGaD
Finasteride—CYP3A4—Tryptophan metabolism—CYP19A1—uterine cancer	2.83e-05	0.00085	CbGpPWpGaD
Finasteride—Asthenia—Doxorubicin—uterine cancer	2.81e-05	0.00123	CcSEcCtD
Finasteride—Dizziness—Epirubicin—uterine cancer	2.8e-05	0.00122	CcSEcCtD
Finasteride—Pruritus—Doxorubicin—uterine cancer	2.77e-05	0.00121	CcSEcCtD
Finasteride—CYP3A5—Metapathway biotransformation—AKR1C3—uterine cancer	2.68e-05	0.000806	CbGpPWpGaD
Finasteride—Rash—Epirubicin—uterine cancer	2.67e-05	0.00117	CcSEcCtD
Finasteride—Dermatitis—Epirubicin—uterine cancer	2.67e-05	0.00116	CcSEcCtD
Finasteride—SRD5A1—Metabolism—CYP19A1—uterine cancer	2.66e-05	0.000798	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—STK11—uterine cancer	2.66e-05	0.000798	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—STK11—uterine cancer	2.66e-05	0.000798	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—CYP19A1—uterine cancer	2.66e-05	0.000798	CbGpPWpGaD
Finasteride—Headache—Epirubicin—uterine cancer	2.65e-05	0.00116	CcSEcCtD
Finasteride—Dizziness—Doxorubicin—uterine cancer	2.59e-05	0.00113	CcSEcCtD
Finasteride—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	2.52e-05	0.000757	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.49e-05	0.000749	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.49e-05	0.000749	CbGpPWpGaD
Finasteride—Rash—Doxorubicin—uterine cancer	2.47e-05	0.00108	CcSEcCtD
Finasteride—Dermatitis—Doxorubicin—uterine cancer	2.47e-05	0.00108	CcSEcCtD
Finasteride—Headache—Doxorubicin—uterine cancer	2.45e-05	0.00107	CcSEcCtD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.38e-05	0.000715	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.38e-05	0.000715	CbGpPWpGaD
Finasteride—CYP3A4—Metapathway biotransformation—AKR1B10—uterine cancer	2.37e-05	0.000713	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—STK11—uterine cancer	2.37e-05	0.000712	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—CYP19A1—uterine cancer	2.37e-05	0.000712	CbGpPWpGaD
Finasteride—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	2.29e-05	0.000687	CbGpPWpGaD
Finasteride—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	2.26e-05	0.000678	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	2.22e-05	0.000668	CbGpPWpGaD
Finasteride—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	2.21e-05	0.000663	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—EP300—uterine cancer	2.12e-05	0.000637	CbGpPWpGaD
Finasteride—CYP3A5—Biological oxidations—CYP19A1—uterine cancer	2.12e-05	0.000636	CbGpPWpGaD
Finasteride—CYP3A5—Metapathway biotransformation—CYP19A1—uterine cancer	2.09e-05	0.000628	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—MTHFR—uterine cancer	2e-05	0.0006	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—MTHFR—uterine cancer	2e-05	0.0006	CbGpPWpGaD
Finasteride—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	1.85e-05	0.000557	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—MTHFR—uterine cancer	1.78e-05	0.000535	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.76e-05	0.000529	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.76e-05	0.000529	CbGpPWpGaD
Finasteride—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	1.62e-05	0.000487	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—NDUFB11—uterine cancer	1.57e-05	0.000473	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—SRD5A2—uterine cancer	1.57e-05	0.000473	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	1.57e-05	0.000471	CbGpPWpGaD
Finasteride—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	1.42e-05	0.000427	CbGpPWpGaD
Finasteride—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	1.34e-05	0.000402	CbGpPWpGaD
Finasteride—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	1.32e-05	0.000397	CbGpPWpGaD
Finasteride—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	1.25e-05	0.000375	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—AKR1B1—uterine cancer	1.14e-05	0.000342	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—STAR—uterine cancer	1.14e-05	0.000342	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—NDUFB11—uterine cancer	1.14e-05	0.000342	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—SRD5A2—uterine cancer	1.14e-05	0.000342	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—PTEN—uterine cancer	1.11e-05	0.000334	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—PTEN—uterine cancer	1.11e-05	0.000334	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—EP300—uterine cancer	1.06e-05	0.000318	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—EP300—uterine cancer	1.06e-05	0.000318	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—PTEN—uterine cancer	9.9e-06	0.000297	CbGpPWpGaD
Finasteride—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	9.84e-06	0.000296	CbGpPWpGaD
Finasteride—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	9.71e-06	0.000292	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—EP300—uterine cancer	9.44e-06	0.000284	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—POLD1—uterine cancer	8.93e-06	0.000268	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—AKR1C1—uterine cancer	8.35e-06	0.000251	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—STAR—uterine cancer	8.23e-06	0.000247	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—AKR1B1—uterine cancer	8.23e-06	0.000247	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—PIK3CA—uterine cancer	7.83e-06	0.000235	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—PIK3CA—uterine cancer	7.83e-06	0.000235	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—RRM2—uterine cancer	7.44e-06	0.000224	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—DCN—uterine cancer	7.23e-06	0.000217	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—PIK3CA—uterine cancer	6.98e-06	0.00021	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—CYP11A1—uterine cancer	6.81e-06	0.000205	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—POLD1—uterine cancer	6.46e-06	0.000194	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—AKR1C3—uterine cancer	6.43e-06	0.000193	CbGpPWpGaD
Finasteride—SRD5A1—Metabolism—AKT1—uterine cancer	6.4e-06	0.000192	CbGpPWpGaD
Finasteride—SRD5A2—Metabolism—AKT1—uterine cancer	6.4e-06	0.000192	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—AKR1C1—uterine cancer	6.04e-06	0.000181	CbGpPWpGaD
Finasteride—AKR1D1—Metabolism—AKT1—uterine cancer	5.7e-06	0.000171	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—RRM2—uterine cancer	5.38e-06	0.000162	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—NDUFB11—uterine cancer	5.29e-06	0.000159	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—SRD5A2—uterine cancer	5.29e-06	0.000159	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—DCN—uterine cancer	5.22e-06	0.000157	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—STK11—uterine cancer	5.01e-06	0.000151	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—CYP19A1—uterine cancer	5.01e-06	0.000151	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—CYP11A1—uterine cancer	4.92e-06	0.000148	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—AKR1C3—uterine cancer	4.65e-06	0.00014	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—STAR—uterine cancer	3.82e-06	0.000115	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—AKR1B1—uterine cancer	3.82e-06	0.000115	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—MTHFR—uterine cancer	3.76e-06	0.000113	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—STK11—uterine cancer	3.62e-06	0.000109	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—CYP19A1—uterine cancer	3.62e-06	0.000109	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—POLD1—uterine cancer	3e-06	9.02e-05	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—AKR1C1—uterine cancer	2.81e-06	8.44e-05	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—MTHFR—uterine cancer	2.72e-06	8.18e-05	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—RRM2—uterine cancer	2.5e-06	7.52e-05	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—DCN—uterine cancer	2.43e-06	7.3e-05	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—CYP11A1—uterine cancer	2.29e-06	6.88e-05	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—AKR1C3—uterine cancer	2.16e-06	6.49e-05	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—PTEN—uterine cancer	2.09e-06	6.29e-05	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—EP300—uterine cancer	2e-06	6e-05	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—STK11—uterine cancer	1.68e-06	5.06e-05	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—CYP19A1—uterine cancer	1.68e-06	5.06e-05	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—PTEN—uterine cancer	1.51e-06	4.55e-05	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—PIK3CA—uterine cancer	1.48e-06	4.44e-05	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—EP300—uterine cancer	1.44e-06	4.34e-05	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—MTHFR—uterine cancer	1.27e-06	3.8e-05	CbGpPWpGaD
Finasteride—CYP3A7—Metabolism—AKT1—uterine cancer	1.21e-06	3.63e-05	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—PIK3CA—uterine cancer	1.07e-06	3.21e-05	CbGpPWpGaD
Finasteride—CYP3A5—Metabolism—AKT1—uterine cancer	8.72e-07	2.62e-05	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—PTEN—uterine cancer	7.04e-07	2.12e-05	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—EP300—uterine cancer	6.71e-07	2.02e-05	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—PIK3CA—uterine cancer	4.96e-07	1.49e-05	CbGpPWpGaD
Finasteride—CYP3A4—Metabolism—AKT1—uterine cancer	4.06e-07	1.22e-05	CbGpPWpGaD
